Clinigen to acquire US rights to Novartis cancer drug Proleukin

This article was originally published here

Proleukin is approved in the US for the treatment of metastatic melanoma and metastatic renal cell carcinoma. As per the terms, Clinigen will make an initial payment of

The post Clinigen to acquire US rights to Novartis cancer drug Proleukin appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply